ciprofloxacin has been researched along with Kidney Failure in 20 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antibiotic nitrofurantoin is commonly used to treat uncomplicated urinary tract infections." | 7.81 | Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. ( Gandhi, S; Garg, AX; Jain, AK; Liu, AR; McArthur, E; Moist, L; Singh, N; Sood, MM, 2015) |
| "The purpose of this study is to describe clinical characteristics of Salmonella bacteremia in adult patients and analyze ciprofloxacin-nonsusceptible isolates." | 7.81 | Clinical characteristics in adult patients with Salmonella bacteremia and analysis of ciprofloxacin-nonsusceptible isolates. ( Cheng, MW; Lee, CM; Lin, CC; Liu, CP; Shih, SC; Wang, NY; Weng, LC; Wu, AY, 2015) |
| " After intravenous dosing of ciprofloxacin (10-30 mg kg(-1)), ciprofloxacin levels in plasma and brain were measured in normal rats (Wistar, male, 10-week-old) and those with acute renal and hepatic injuries which were induced by uranyl nitrate and carbon tetrachloride (CCl4), respectively." | 5.30 | Distribution of ciprofloxacin into the central nervous system in rats with acute renal or hepatic failure. ( Hirano, H; Ichikawa, N; Iwamoto, K; Naora, K, 1999) |
| "Oral ciprofloxacin therapy was continued for 10 days and the patient remained free of symptoms with formed stools thereafter." | 5.29 | Pseudomonas aeruginosa as a cause of infectious diarrhea successfully treated with oral ciprofloxacin. ( Porco, FV; Visconte, EB, 1995) |
| "The antibiotic nitrofurantoin is commonly used to treat uncomplicated urinary tract infections." | 3.81 | Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. ( Gandhi, S; Garg, AX; Jain, AK; Liu, AR; McArthur, E; Moist, L; Singh, N; Sood, MM, 2015) |
| "The purpose of this study is to describe clinical characteristics of Salmonella bacteremia in adult patients and analyze ciprofloxacin-nonsusceptible isolates." | 3.81 | Clinical characteristics in adult patients with Salmonella bacteremia and analysis of ciprofloxacin-nonsusceptible isolates. ( Cheng, MW; Lee, CM; Lin, CC; Liu, CP; Shih, SC; Wang, NY; Weng, LC; Wu, AY, 2015) |
| "This analysis demonstrates for the first time that, used in a stepwise fashion, ciprofloxacin and leflunomide are effective and safe treatments for BK viremia in PRTR." | 3.80 | A novel treatment regimen for BK viremia. ( Cheam, H; Ettenger, RB; Malekzadeh, MH; Tsai, EW; Zaman, RA, 2014) |
| " No dosage modifications were made in patients with renal impairment." | 2.68 | The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. ( Hedges, AJ; Jones, EM; Lovering, AM; MacGowan, AP; McMullin, CM; Reeves, DS; White, LO, 1997) |
| "Malacoplakia is a rare chronic inflammatory disease that most commonly involves the genitourinary tract with a wide spectrum of clinical presentation." | 1.48 | Bilateral hydroureteronephrosis with renal failure caused by malacoplakia. ( Audino, P; Cavallone, B; Di Stasio, A; Serao, A; Tiranti, D; Vota, P, 2018) |
| "NC, with renal failure secondary to bilateral dysplastic kidneys, received an LRD renal transplant (tx) at 17 months of age." | 1.40 | Treatment of BK virus-associated nephropathy with CMX001 after kidney transplantation in a young child. ( Habib, S; Latiolais, LS; McClure, GB; Reisman, L; Vanchiere, JA, 2014) |
| " The relationship between the efficacies of these 3 dosage schemes could have been predicted by AUC above MIC and AUIC, but not by AUC/MIC or time above MIC." | 1.33 | Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval? ( Czock, D; Rasche, FM, 2005) |
| "To define in critically ill patients receiving intravenous (iv) ciprofloxacin (200 mg or 400 mg twice daily) and undergoing routine therapeutic drug monitoring (TDM) the interindividual pharmacokinetic variability and the reliable pharmacodynamic breakpoint enabled by these fixed dosing regimens according to the PK/PD principles and to the pattern of susceptibility to this antibiotic." | 1.33 | Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. ( Furlanut, M; Pavan, F; Pea, F; Poz, D; Viale, P, 2006) |
| "Levofloxacin clearance was substantially increased during both CVVH and CVVHDF, while ciprofloxacin clearance was affected less." | 1.31 | Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. ( Abraham, E; Fish, DN; Malone, RS; Teitelbaum, I, 2001) |
| " These results suggest an increased bioavailability of ciprofloxacin in nephrectomized rats, which was confirmed by a nonlinear mixed-effect model." | 1.30 | Influence of renal failure on ciprofloxacin pharmacokinetics in rats. ( Carbon, C; Dautrey, S; Farinotti, R; Laouari, D; Nouaille-Degorce, B; Tod, M; Veau, C, 1998) |
| " After intravenous dosing of ciprofloxacin (10-30 mg kg(-1)), ciprofloxacin levels in plasma and brain were measured in normal rats (Wistar, male, 10-week-old) and those with acute renal and hepatic injuries which were induced by uranyl nitrate and carbon tetrachloride (CCl4), respectively." | 1.30 | Distribution of ciprofloxacin into the central nervous system in rats with acute renal or hepatic failure. ( Hirano, H; Ichikawa, N; Iwamoto, K; Naora, K, 1999) |
| "Percutaneous drainage of renal hydatid cysts is a safe and effective method for preventing renal loss, and decreasing morbidity and the duration of hospital stay." | 1.29 | Percutaneous drainage of renal hydatid cyst: early results and follow-up. ( Agarwal, MR; Goel, MC; Misra, A, 1995) |
| " The mean Cmax was 3." | 1.29 | Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. ( Bailie, GR; Echols, M; Kowalsky, SF; McCormick, E; Schwartz, MT, 1993) |
| "Oral ciprofloxacin therapy was continued for 10 days and the patient remained free of symptoms with formed stools thereafter." | 1.29 | Pseudomonas aeruginosa as a cause of infectious diarrhea successfully treated with oral ciprofloxacin. ( Porco, FV; Visconte, EB, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (50.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavallone, B | 1 |
| Serao, A | 1 |
| Audino, P | 1 |
| Di Stasio, A | 1 |
| Tiranti, D | 1 |
| Vota, P | 1 |
| Zaman, RA | 1 |
| Ettenger, RB | 1 |
| Cheam, H | 1 |
| Malekzadeh, MH | 1 |
| Tsai, EW | 1 |
| Reisman, L | 1 |
| Habib, S | 1 |
| McClure, GB | 1 |
| Latiolais, LS | 1 |
| Vanchiere, JA | 1 |
| Singh, N | 1 |
| Gandhi, S | 1 |
| McArthur, E | 1 |
| Moist, L | 1 |
| Jain, AK | 1 |
| Liu, AR | 1 |
| Sood, MM | 1 |
| Garg, AX | 1 |
| Cheng, MW | 1 |
| Lee, CM | 1 |
| Wang, NY | 1 |
| Wu, AY | 1 |
| Lin, CC | 1 |
| Weng, LC | 1 |
| Liu, CP | 1 |
| Shih, SC | 1 |
| Monescillo Francia, A | 1 |
| Czock, D | 1 |
| Rasche, FM | 1 |
| Pea, F | 1 |
| Poz, D | 1 |
| Viale, P | 1 |
| Pavan, F | 1 |
| Furlanut, M | 1 |
| Goel, MC | 1 |
| Agarwal, MR | 1 |
| Misra, A | 1 |
| Xie, W | 1 |
| Li, X | 1 |
| Kowalsky, SF | 1 |
| Echols, M | 1 |
| Schwartz, MT | 1 |
| Bailie, GR | 1 |
| McCormick, E | 1 |
| Porco, FV | 1 |
| Visconte, EB | 1 |
| Iakovlev, SV | 1 |
| Iakovlev, VP | 1 |
| Izotova, GN | 1 |
| Jones, EM | 1 |
| McMullin, CM | 1 |
| Hedges, AJ | 1 |
| Lovering, AM | 1 |
| White, LO | 1 |
| Reeves, DS | 1 |
| MacGowan, AP | 1 |
| Nouaille-Degorce, B | 1 |
| Veau, C | 1 |
| Dautrey, S | 2 |
| Tod, M | 1 |
| Laouari, D | 2 |
| Carbon, C | 2 |
| Farinotti, R | 2 |
| Rabbaa, L | 1 |
| Lacour, B | 1 |
| Naora, K | 1 |
| Ichikawa, N | 1 |
| Hirano, H | 1 |
| Iwamoto, K | 1 |
| Lomaestro, BM | 1 |
| Malone, RS | 1 |
| Fish, DN | 1 |
| Abraham, E | 1 |
| Teitelbaum, I | 1 |
| Dhawan, A | 1 |
| Marwaha, RK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| BK Viremia and BK Virus Nephropathy Post Kidney Transplant Comparison of New Practices With Traditional Approach: A Combined Retrospective Chart Review and Prospective Observational Study[NCT02758288] | 0 participants (Actual) | Observational | 2015-09-30 | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ciprofloxacin and Kidney Failure
| Article | Year |
|---|---|
[Pharmacokinetics of fluoroquinolones in patients with renal insufficiency].
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Ofloxacin; Pefloxacin; Quinolones; R | 1995 |
Fluoroquinolone-induced renal failure.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Renal Insufficiency | 2000 |
1 trial available for ciprofloxacin and Kidney Failure
| Article | Year |
|---|---|
The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease.
Topics: Abdomen; Adult; Aged; Bacteremia; Ciprofloxacin; Creatine; Dose-Response Relationship, Drug; Female; | 1997 |
17 other studies available for ciprofloxacin and Kidney Failure
| Article | Year |
|---|---|
Bilateral hydroureteronephrosis with renal failure caused by malacoplakia.
Topics: Aged; Anti-Bacterial Agents; Ascorbic Acid; Ciprofloxacin; Female; Humans; Hydronephrosis; Malacopla | 2018 |
A novel treatment regimen for BK viremia.
Topics: Adolescent; BK Virus; Child; Ciprofloxacin; Female; Fluoroquinolones; Glomerular Filtration Rate; Hu | 2014 |
Treatment of BK virus-associated nephropathy with CMX001 after kidney transplantation in a young child.
Topics: Administration, Oral; Biopsy; BK Virus; Child, Preschool; Ciprofloxacin; Creatinine; Cytosine; DNA, | 2014 |
Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Ciprofl | 2015 |
Clinical characteristics in adult patients with Salmonella bacteremia and analysis of ciprofloxacin-nonsusceptible isolates.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; Base Sequence; beta-Lactamases; | 2015 |
[Spontaneous bacterial peritonitis].
Topics: Anti-Bacterial Agents; Cefotaxime; Ciprofloxacin; Humans; Ofloxacin; Peritonitis; Primary Prevention | 2009 |
Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval?
Topics: Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Computer Simulation; Dose-Response Relations | 2005 |
Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective.
Topics: Analysis of Variance; Anti-Bacterial Agents; Area Under Curve; Bacterial Infections; Chromatography, | 2006 |
Percutaneous drainage of renal hydatid cyst: early results and follow-up.
Topics: Adult; Albendazole; Ciprofloxacin; Drainage; Echinococcosis; Female; Follow-Up Studies; Humans; Kidn | 1995 |
Experience in treating secondary systemic mycotic infection after severe burns associated with electric injury.
Topics: Adult; Amputation, Surgical; Burns, Electric; Candidiasis; Ciprofloxacin; Fluconazole; Humans; Male; | 1995 |
Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD.
Topics: Administration, Oral; Adult; Ciprofloxacin; Female; Half-Life; Humans; Least-Squares Analysis; Male; | 1993 |
Pseudomonas aeruginosa as a cause of infectious diarrhea successfully treated with oral ciprofloxacin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Cross Infection | 1995 |
Influence of renal failure on ciprofloxacin pharmacokinetics in rats.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Infusions, Parenteral; Kidney; | 1998 |
Influence of renal failure on intestinal clearance of ciprofloxacin in rats.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Bile; Chromatography, High Pressure Liquid; Ciprof | 1999 |
Distribution of ciprofloxacin into the central nervous system in rats with acute renal or hepatic failure.
Topics: Animals; Anti-Infective Agents; Central Nervous System; Ciprofloxacin; Liver Failure; Male; Rats; Ra | 1999 |
Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Critical Illness; Female; Hemofiltration; Humans; | 2001 |
Acute glomerulonephritis in multi-drug resistant Salmonella typhi infection.
Topics: Blood Chemical Analysis; Child; Ciprofloxacin; Fever; Glomerulonephritis; Humans; Male; Peritoneal D | 1992 |